Competition law vs patent rights: NCLAT rules CCI has no power to probe patented product disputes; upholds case against Swiss drugmaker Vifor
Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -
Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -
The NCLAT ruled that the CCI cannot investigate disputes concerning patented products, asserting the Patent Act's precedence over the Competition Act. This decision dismissed an appeal against the CCI's closure of a complaint against Vifor International regarding its patented drug, Ferric Carboxymaltose (FCM) injection. What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
